SPRB logo

SPRB
Spruce Biosciences Inc

4,958
Mkt Cap
$96.45M
Volume
70,423.00
52W High
$240.00
52W Low
$4.28
PE Ratio
-1.33
SPRB Fundamentals
Price
$69.90
Prev Close
$70.30
Open
$70.61
50D MA
$63.40
Beta
1.14
Avg. Volume
36,668.40
EPS (Annual)
-$50.83
P/B
2.26
Rev/Employee
$0.00
$18.61
Loading...
Loading...
News
all
press releases
Spruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Spruce Biosciences, Inc. (Spruce Biosciences) (NASDAQ: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with...
Business Wire·7h ago
News Placeholder
More News
News Placeholder
Wall Street Analysts Believe Spruce Biosciences (SPRB) Could Rally 181.21%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 181.2% in Spruce Biosciences (SPRB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·18d ago
News Placeholder
Spruce Biosciences, Inc. (NASDAQ:SPRB) Receives Average Recommendation of "Hold" from Analysts
Shares of Spruce Biosciences, Inc. (NASDAQ:SPRB - Get Free Report) have been given an average recommendation of "Hold" by the eight research firms that are presently covering the company...
MarketBeat·24d ago
News Placeholder
Does Spruce Biosciences (SPRB) Have the Potential to Rally 208.32% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 208.3% in Spruce Biosciences (SPRB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·1mo ago
News Placeholder
HC Wainwright Issues Optimistic Outlook for SPRB Earnings
Spruce Biosciences, Inc. (NASDAQ:SPRB - Free Report) - Research analysts at HC Wainwright increased their Q1 2026 earnings per share estimates for shares of Spruce Biosciences in a note issued to...
MarketBeat·1mo ago
News Placeholder
Spruce Biosciences (NASDAQ:SPRB) Announces Quarterly Earnings Results
Spruce Biosciences (NASDAQ:SPRB - Get Free Report) posted its quarterly earnings results on Monday. The company reported ($9.58) earnings per share for the quarter, missing the consensus estimate of...
MarketBeat·1mo ago
News Placeholder
Spruce Biosciences (NASDAQ:SPRB) Given New $170.00 Price Target at Citizens Jmp
Citizens Jmp lowered their price target on shares of Spruce Biosciences from $180.00 to $170.00 and set a "market outperform" rating on the stock in a research note on Tuesday...
MarketBeat·1mo ago
News Placeholder
Spruce Biosciences (NASDAQ:SPRB) Earns "Buy" Rating from HC Wainwright
HC Wainwright reiterated a "buy" rating and set a $200.00 price target on shares of Spruce Biosciences in a research report on Tuesday...
MarketBeat·1mo ago
News Placeholder
Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical...
Business Wire·1mo ago
News Placeholder
Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical...
Business Wire·1mo ago
<
1
2
...
>

Latest SPRB News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.